Compare Adaptive Biotechnologies Corp (ADPT) vs Estee Lauder Companies Inc (EL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Estee Lauder Companies Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.96 (market cap $3.33B), while Estee Lauder Companies Inc trades at $81.3 (market cap $30.55B). The key difference: Estee Lauder Companies Inc is far larger — about 9.2× Adaptive Biotechnologies Corp's market cap, and Estee Lauder Companies Inc pays a 1.66% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | EL | |
|---|---|---|
Market Cap | $3.33B | $30.55B |
Sector | Health | Consumer Staples |
52-Week High | $22.37 | $119.61 |
52-Week Low | $10.24 | $67.23 |
Enterprise Value | $3.19B | $36.72B |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Estée Lauder (EL) trades at $84.44, up 0.87% with a bullish technical signal and recent earnings beats. The stock shows strong momentum with three consecutive quarterly EPS beats and a consensus price target of $90.60. However, fundamentals reveal challenges with negative net income of -$1.13B in 2025 and elevated P/E of 147.8, though gross margins remain robust at 74.71%. Recent news highlights strategic investments and product innovation, including the Scent Scanner launch with Jo Malone London.
The outlook is mixed: technical strength and analyst optimism support upside to $90+, but high valuation and profitability concerns pose risks. Investment opportunity lies in execution of growth initiatives and margin recovery, while key risks include competitive pressures and macroeconomic headwinds affecting consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →
